Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. November 2025 09:15 ET | Quelle: Longeveron

Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)

Cellular therapy laromestrocel Phase 2 clinical trial data in Alzheimer's disease selected for poster presentation at CTAD 2025.
06. Oktober 2025 09:15 ET | Quelle: Longeveron

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Longeveron will participate in the 4th Annual ROTH Healthcare Opportunities Conference October 9, 2025 in New York City.
02. Mai 2025 08:30 ET | Quelle: Longeveron

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Longeveron (LGVN) will report Q1 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close.
11. März 2025 08:30 ET | Quelle: Longeveron

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

Longeveron positive Phase 2 clinical trial data in Alzheimer's disease published in peer reviewed journal Nature Medicine.